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LETTER TO THE EDITOR
Journal  of  the College of  Physicians and Surgeons Pakistan 2020,  Vol.  30 (Supplement 2 COVID-19):S180S180
Vitamin D in COVID-19 Pneu-
monia: High Yield with Low
Risk
Sir,
The  novel  coronavirus  disease  2019  (COVID-19)  is  a  global
public health problem with particularly poor outcomes in the
elderly.  The  disease  pathogenesis  and  presentation  is  still
evolving. Vitamin D is a fat-soluble, secosterol that exists in two
forms: vitamin D2 and D3. It is obtained mostly from food with a
small portion synthesised by sunlight. The association of low
vitamin D levels with increased susceptibility to upper respira-
tory tract infections (URTIs) is known in the literature.1 A meta-a-
nalysis did show benefit of taking vitamin D supplementation
among  patients  with  low  25  hydroxy-vitamin  D  levels
presenting with URTIs.3,4 There are studies suggesting utility of
vitamin D both in prevention, and in decreasing severity and
mortality among patients with COVID-19 pneumonia. The mech-
anism is linked to development of antimicrobial peptides and
activation of dendritic cells, macrophages, T and B lymphocytes
through utilisation of vitamin D receptors (VDR) that improve
immunity  and  decrease  inflammatory  response  against
COVID-19.4,5 The virus interacts with ACE2 receptors on type II
pneumocytes  and  leads  to  cell  death.  Vitamin  D  also  has
immunomodulatory properties that  downregulate activity  of
pro-inflammatory  cytokines  and  further  suppress  ACE2
receptor activity.4,5 This protective effect of vitamin D can be
achieved by a single oral vitamin D3 dose (2000 IU).
The COVID-19 disease severity may be linked to location of coun-
tries, which in turn, determines the extent of sunlight exposure.
In this regard, it is reported that dermal production of vitamin D
from solar  UVB between  October  to  March  is  low  above  35
degrees  latitude.  Countries  included  in  these  regions  are
predominantly inhabited by elderly, who are predisposed to
higher probability of cardio-pulmonary and metabolic comor-
bidities. This might be a reason for such high incidence and
mortality from COVID-19 in Western Europe and America. The
cross-sectional analysis of 20 European countries does prove
the notion that majority of  people who suffered death were
elderly and likely vitamin D deficient, based on data analysis
from  those  regions.  The  problem  is  exacerbated  during
prolonged  lockdown,  where  people  are  not  getting  enough
sunlight exposure and; hence, stressed on already deficient
vitamin D levels.
Vitamin D can be used as supplementary therapy in patients to
boost up the innate immunity and to combat mild to moderate
COVID-19  pneumonia.  Micronutrient  supplementation
including vitamin D and C should be started early in the disease
process. Though vitamin D utility in COVID-19-related pneu-
monia has not been evaluated, trials are underway to further
test its efficacy in COVID-19-associated pneumonia; and the
results are expected in the coming months. The current treat-
ments in use are very expensive and need validation through
superiority  designs.  Early  administration  of  vitamin  D  may
prove  beneficial  in  reducing  the  severity  of  symptoms  and
possibly  hospitalisation  rates  in  low  resource  settings  like
Pakistan.
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